Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax.
Bazinet A, Desikan SP, Li Z, Rodriguez-Sevilla JJ, Venugopal S, Urrutia S, Montalban-Bravo G, Sasaki K, Chien KS, Hammond D, Kanagal-Shamanna R, Ganan-Gomez I, Kadia TM, Borthakur G, DiNardo CD, Daver NG, Jabbour EJ, Ravandi F, Kantarjian H, Garcia-Manero G.
Bazinet A, et al. Among authors: li z.
Clin Cancer Res. 2024 Apr 1;30(7):1319-1326. doi: 10.1158/1078-0432.CCR-23-2860.
Clin Cancer Res. 2024.
PMID: 38300723